Risk factors include admission to an intensive care unit, mechanical ventilation, previous use of antibiotics, poor general health and recent receipt of transplanted organs or stem cells. 7, 10 Infection with KPC-producing organisms is associated with a high mortality (up to 40%-50%) and constitutes an independent risk factor of death. 5, 7, 10 The prevalence of KPC-producing pathogens in Canada is currently unknown because laboratories may not be using the most sensitive methods for detection.
Diagnosis
The routine methods of detection and the automated systems commonly used by clinical laboratories may fail to consistently detect KPC-producing organisms. The pathogens may test as "susceptible" to carbapenems such as meropenem and imipenem using the usual interpretive criteria. In 2008, 10 isolates of K. pneumoniae were referred to the Ontario Public Health Laboratories for further testing. 11, 12 The initial results of susceptibility testing of 1 of the 10 isolates using an automated method suggested that the organism was susceptible to meropenem. However, the initial results of testing using routine clinical laboratory methods showed general resistance to all lactams, with complete or intermediate resistance to meropenem, which raised the possibility of KPC production. This discrepancy could mislead a clinician into thinking that the carbapenem class of antibiotics is useful. When the 10 isolates were subsequently tested using phenotypic and molecular methods, all were confirmed to be producers of KPC. Canadian laboratories should screen for KPC production, as recently recommended by the 2009 Clinical Laboratory Standards Institute. 13 KPC production should be suspected if in vitro testing shows resistance or reduced susceptibility to a carbapenem. Isolates of K. pneumoniae that are resistant to any of the extended-spectrum cephalosporins but that test "susceptible" to the carbapenems should also be evaluated for possible production of KPC. Screening with ertapenem is preferred, since this agent is more susceptible than other carbapenems to KPC hydrolysis. 13, 14 Confirmation of carbapenemase activity can be performed phenotypically using the modified Hodge test. 15 Public health laboratories and other reference laboratories that can perform molecular testing should specifically confirm the presence of the bla KPC gene using techniques such as the polymerase chain reaction.
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Management
Treatment of infections with KPC-producing organisms is problematic because of limited therapeutic options. 2, 16 Fluoroquinolones, aminoglycosides or cotrimoxazole may be used if the organism is susceptible. More commonly, the pathogen will be resistant to these antibiotics, as shown by recent trends of resistance in Enterobacteriaceae. 17 Anecdotal reports suggest that tigecycline (a glycylcycline) or colistin (a polymyxin) may be effective. 18, 19 However, tigecycline may not be suitable for septicemia, and colistin is associated with nephrotoxic and neurotoxic effects.
Despite the absence of definitive evidence, it would seem prudent to isolate infected patients and take contact-related precautions because of the potential for nosocomial transmission. 20 Resistance genes encoded by plasmids have a theoretical risk of rapid transmission from one species to the next, which implies that rigorous measures to limit the spread of infection will be crucial. The emergence of KPC-producing organisms in Canada reinforces the need for antimicrobial stewardship as a strategy to control the spread of these extremely drug-resistant organisms. 21 
